Smith Chas P & Associates PA Cpas Has $13.63 Million Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Smith Chas P & Associates PA Cpas increased its holdings in Novo Nordisk A/S by 143.6%, reaching a total of 197,466 shares valued at approximately $13.63 million.
• Several institutional investors have also boosted their positions in Novo Nordisk, with notable increases including Generate Investment Management Ltd growing its stake by 301.7% during the same period.
• Novo Nordisk A/S reported earnings of $0.97 per share, exceeding analyst expectations, while the company’s stock has fluctuated between a twelve-month low of $45.05 and a high of $121.34.

Smith Chas P & Associates PA Cpas grew its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 143.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 197,466 shares of the company's stock after buying an additional 116,413 shares during the period. Smith Chas P & Associates PA Cpas' holdings in Novo Nordisk A/S were worth $13,629,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in NVO. Elser Financial Planning Inc raised its holdings in Novo Nordisk A/S by 241.7% during the second quarter. Elser Financial Planning Inc now owns 12,692 shares of the company's stock worth $876,000 after acquiring an additional 8,978 shares in the last quarter. GC Wealth Management RIA LLC increased its position in shares of Novo Nordisk A/S by 47.5% in the second quarter. GC Wealth Management RIA LLC now owns 13,932 shares of the company's stock worth $962,000 after purchasing an additional 4,489 shares during the period. Cairn Investment Group Inc. lifted its stake in Novo Nordisk A/S by 4.5% during the second quarter. Cairn Investment Group Inc. now owns 10,328 shares of the company's stock worth $713,000 after purchasing an additional 446 shares during the last quarter. Generate Investment Management Ltd grew its holdings in shares of Novo Nordisk A/S by 301.7% during the 2nd quarter. Generate Investment Management Ltd now owns 160,539 shares of the company's stock valued at $11,080,000 after purchasing an additional 120,577 shares during the last quarter. Finally, Sound Income Strategies LLC raised its position in Novo Nordisk A/S by 194.5% in the second quarter. Sound Income Strategies LLC now owns 2,692 shares of the company's stock valued at $186,000 after purchasing an additional 1,778 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $55.61 on Monday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market cap of $248.30 billion, a P/E ratio of 15.28, a P/E/G ratio of 2.11 and a beta of 0.66. The stock's fifty day moving average price is $56.03 and its 200-day moving average price is $64.38. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $121.34.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is 22.53%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. TD Cowen decreased their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, August 19th. Berenberg Bank raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Wednesday, September 17th. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a research report on Wednesday, August 13th. Finally, Hsbc Global Res downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and a consensus price target of $75.33.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.